“Multidrug resistant tuberculosis is a growing threat, and bedaquiline is essential to curing it. Generic bedaquiline will drive down the cost of the drug by over 60%, allowing far more communities to access and distribute treatment. Evergreening the patent will cost so many lives over the next four years, which Johnson & Johnson knows. They must drop their efforts to enforce the secondary patents.”
"Tell Johnson and Johnson that evergreening their patent on bedaquiline, which will deny millions of people access to live-saving treatment, is a violation of their corporate credo: https://secure.ethicspoint.com/domain… Tell them on twitter: https://twitter.com/JNJNews and https://twitter.com/JNJGlobalHealth Tell them on facebook: https://www.facebook.com/jnj/ Tell them on instagram: https://www.instagram.com/jnj/?hl=en And tell them wherever else you can. Tell your friends. Tell your family. Tell the Internet. This must not be allowed to happen.
Big thanks to TB expert Dr. Carole Mitnick and MSF’s Christophe Perrin for helping me to understand the complexities of drug patents!"
You’re right that corporate incentives are completely messed up, but when something like this generates negative press it hurts their brand and potentially their bottom line down the road as a result. If they do reverse course it certainly won’t be out of the goodness of their hearts.
Not like we can buy the drug elsewhere /:
This is why I am pro-public healthcare. A market isn’t a free market if I die when I don’t buy your product.
That was very well articulated!
No, but there’s a whole lotta stuff branded J&J that you CAN buy elsewhere
These corporations all own many brands.